AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback